A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF THE COMBINATION OF BELEODAQ-CHOP OR FOLOTYN-COP TO THE CHOP REGIMEN ALONE IN NEWLY DIAGNOSED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
- Registry ID
- SPI-BEL-301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ACROTECH BIOPHARMA INC.
- Start date
- 2025-02-20
- Last update
- 2024-03-19
Conditions
- PERIPHERAL T CELL LYMPHOMA
Related clinical trials
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A PHASE 3, RANDOMIZED, OPEN LABEL STUDY TO INVESTIGATE THE EFFICACY AND STAFETY OF ITK INHIBITOR SOQUELITINIB VERSUS PHYSICIAN'S CHOICE STANDARD OF CARE TREATMENT (SELECTED SINGLE AGENT) IN PARTICIPANTS WITH RELAPSED/REFRACTORYPERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED ,FOLLICULAR HELPER T-CELL LYMPHOMAS,OR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA
- PHASE 1B, RANDOMIZED, DOSE OPTIMIZATION STUDY TO ASSESS THE ANTI-TUMOR
ACTIVITY, SAFETY, AND PHARMACOKINETICS OF TLN-254 IN PATIENTS WITH RELAPSED
OR REFRACTORY T-CELL LYMPHOMA
- "A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, AND PREDNISONE (CHEP-BV) FOLLOWED BY BV CONSOLIDATION IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS."
View on source registry